MRNA (modernatx.com) Net earnings per share (EPS TTM)

Moderna, Inc. (MRNA) growth is based on its independence from economic cycles and the success of clinical trials. The 12-month rolling earnings per share history visualizes this trend, where the value -7.11 represents the latest figure. Patented mRNA technologies for combating cancer and large-scale alliances with government institutions worldwide serve as the foundation.

MRNA (Moderna Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/14/2026

Moderna Corp (MRNA) - metric breakdowns and financial figures

- current quotes and average value forecast:

Price Chart Moderna Corp|MRNA - Broker Consensus Forecast

- business market valuation indicators:

Market Capitalization Moderna Inc|MRNA - Full Business Value

- business book valuation details:

Book Value per Share Moderna|MRNA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio modernatx.com|MRNA - Cumulative Company Assets

- debt and solvency information:

- net income and valuation multiples indicators:

MRNA - Net Financial Result|Expected Profit Moderna, Inc.|MRNA - Price to Earnings Ratio|Future Price to Earnings modernatx.com|MRNA - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Moderna|MRNA - Operating profit before amortization|Net earnings per share (EPS TTM) Moderna|MRNA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months modernatx.com|MRNA - Earnings per share increase in current year|Net earnings per share growth forecast for next year Moderna, Inc.

- revenue and sales proceeds data:

MRNA - Company Sales Volume|Projected Sales Volume modernatx.com|MRNA - P/S Multiple|Forward Price-to-Revenue Multiple Moderna Therapeutics

Fundamental company analysis:MRNA - Moderna Therapeutics

Net income per share over 12 months measures the portion of equity attributable to a single security, allowing for an assessment of real business profitability without accounting for share dilution. By analyzing the 12-month net income per share snapshot, an investor determines the capital stability of Moderna, Inc. (MRNA), where the technological superiority of the mRNA platform offsets the decline in demand for legacy products, maintaining margins during the portfolio transformation.

Main competitors

SMMT - Earnings per share for the last twelve months|PCVX (Vaxcyte) - Earnings per share for the last 12 months|TARS: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months CRMD (CorMedix Corp)|MCRB (Seres Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Spero Therapeutics SPRO|Net earnings per share (EPS TTM) SCYX|Net earnings per share for the last 12 months AN2 Bio ANTX|PolyPid - Net earnings per share for the last 12 months|Net earnings per share for the last four quarters YS Biopharma Co., Ltd. (LSB)|Iterum Therapeutics PLC - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BiomX PHGE|soligenix.com (SNGX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months 60 Degrees Pharma (SXTP)|Earnings per share for the last twelve months Oragenics|Earnings per share for the last 12 months OPGN (OpGen Corporation)